Skip to main content
. Author manuscript; available in PMC: 2022 Apr 28.
Published in final edited form as: Oncogene. 2007 Oct 29;27(18):2552–2560. doi: 10.1038/sj.onc.1210896

Figure 1.

Figure 1.

Distribution of CCN3 expression in benign melanocytic nevi and in malignant melanoma. Immunohistochemistry was performed with antibodies specific for CCN3. Melanocytic cells were identified with HMB45 staining and count CCN3 positive cells in HMB45-positive tumor clusters. CCN3 is expressed at the epidermal–dermal junction in junctional nevi and in superficial spreading melanomas (SSM). Faint CCN3 expression is seen in intradermal nevi, in the dermal invasion portion of SSM, in nodular melanomas (NM) and in melanomas metastatic to lymph nodes (LN metastasis). Control: staining with rabbit sera (original magnification × 400, scale bar 100 μm).